• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Teva reintroduces generic Depo-Provera contraceptive in U.S.

September 25, 2017 By Sarah Faulkner

Teva PharmaceuticalTeva Pharmaceuticals (NYSE:TEVA) said today that it is reintroducing the generic equivalent to the Depo-Provera contraceptive in the U.S.

The injectable medroxyprogesterone acetate suspension brought in $211 million in sales this year in the U.S., according to the Jerusalem-based pharma giant.

“This reintroduction brings an additional product to a market that was previously lacking in options,” Hafrun Fridriksdottir, EVP & president of Teva’s global generics R&D, said in prepared remarks. “In addition to its importance to patients who will benefit from access to this medicine, this reintroduction holds significant importance to Teva and our generics R&D priorities.”

The move comes just a few days after Teva said it planned to sell off its global women’s health business in a $2.48 billion deal. The company plans to use the funds to repay term loan debt.

CVC Capital Partners Fund VI is set to acquire a portfolio of products including Teva’s Ovaleap, Zoely, Seasonique, Colpotrophine, Actonel and others, for $703 million in cash.

Teva also inked an agreement with Foundation Consumer Healthcare for $675 million in cash. According to that deal, Foundation Consumer Healthcare will acquire Teva’s Plan B One-Step and its brands of emergency contraception, including Take Action and Next Choice One Dose.

The transactions are expected to close by the end of the year.

The pharmaceutical company plans to divest of its oncology and pain businesses in Europe, narrowing its focus on CNS and respiratory conditions as its therapeutic areas of focus.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Featured, Pharmaceuticals, Wall Street Beat, Women's Health Tagged With: Teva Pharmaceuticals

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS